Transaction · 0001231919-26-000959

5Am Partners VII, LLC

5AM Partners VII, LLC, 10%, reported an open-market or private sale at Skye Bioscience, Inc. involving 1830.000000 shares for an estimated $695.40. Reported holdings after the transaction were 55663.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market sellSEC transaction code S10%
SKYESkye Bioscience, Inc.
Trade date
Aug 18, 2026
Filing date
Aug 20, 2026
View on SEC Insider profile
Estimated value-$695Shares × reported price
Shares traded1.83k$0.38 per share
Holdings after55.6kIndirect · By 5AM Co-Investors II, L.P.
% of reported position traded3.18%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 57,493 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

SKYE price since this filing

Daily closing prices, with the filing date and available return windows
SKYE · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +128.6%1w ago +92.9%1d ago +46.4%
Returns since7d +596.4%30d +528.6%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001231919-26-000959
Common Stock
Transaction date
Aug 18, 2026
Filed Aug 20, 2026, 09:57 PM · 2d delay
Shares
1,830 sh
$0.38 per share
Estimated value
-$695
Computed from shares × price
Holdings after
55,663 sh
Indirect · By 5AM Co-Investors II, L.P.
Filing-only score

+4 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector No10% YesOther No
Footnotes & amended
  1. F1

    The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.35 to $0.41 inclusive. The Reporting Persons undertake to provide…

  2. F2

    The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. S…

  3. F3

    The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rockl…

  4. F4

    The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab ar…

  5. F5

    The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.33 to $0.36 inclusive. The Reporting Persons undertake to provide…

Original filing · 0001231919-26-000959
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

SKYE